Trial of Roflumilast in Asthma Management (TRIM)

• Status: Completed
• Trial end date: 2021-07-30
• Target enrollment: 0
• Participant gender: All

Summary

There are currently no treatments to specifically target asthma in obese adults. This pilot study is being conducted to investigate how effective roflumilast is in treating asthma in participants that have a higher BMI. Roflumilast can induce weight loss, which may lead to improved asthma control.

The primary objective of TRIM is to perform a pilot placebo-controlled trial of roflumilast for the treatment of poorly controlled obese asthmatics.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborators: American Lung Association; National Heart, Lung, and Blood Institute (NHLBI)

Criteria

Inclusion Criteria:

• Physician diagnosis of asthma on regular prescribed controller therapy for at least 3 months

• Previous (within five years) evidence of at least a 12% increase in FEV1 after inhaling 2-4 puffs of albuterol or a positive methacholine challenge or patient reported history of improvement of asthma exacerbation after a course of systemic or inhaled corticosteroids

• Age: ≥18 years of age

• Obese: BMI > 30 kg/m2

• Poorly controlled asthma: Asthma Control Test Score < 20, or use of rescue inhaler, on an average of> 2 uses/week for preceding month, or nocturnal asthma awakening, on an average of 1 or more times / week in preceding month, or emergency department (ED)/hospital visit or prednisone course for asthma in past six months.

• Ability and willingness to provide informed consent

Exclusion Criteria:

• Participation in an investigational study within the past 4 weeks

• Physician diagnosis of chronic obstructive pulmonary disease

• Any condition that puts the participant at risk from weight loss as judged by the site physician

• Liver cirrhosis

• Major psychiatric disorders such as generalized anxiety disorder, major depressive disorder, history of suicidal ideation/ attempt, panic disorder, post-traumatic stress disorder, schizophrenia, schizoaffective, substance abuse or other disorders that in the opinion of the study physician that would affect study participation

• > 0 time use of illicit drugs in the past 12 months

• > 0 time use of cannabis in the past 12 months

• Uncontrolled depression as defined by a score of 15 or greater on the depression questions of the PHQ-9

• Suicidal ideation (a score of greater than 0 on Question 9 on the PHQ-9)

• Uncontrolled anxiety as defined by a score of 10 or greater on the anxiety questions of the Generalized Anxiety Disorder 7-item (GAD-7)

• Pregnancy/lactation

• Females of childbearing age who do not agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.

• Greater than 20 pack year smoking history, or smoking within the last 6 months.

• History of bariatric surgery

• Drugs metabolized by cytochrome P450 (rifampicin, phenobarbital, carbamazepine, phenytoin, erythromycin, ketoconazole, cimetidine, fluvoxamine, enoxacin, oral contraceptives containing ethinyl estradiol with gestodene).

• Currently on roflumilast or theophylline (patient may wash out of these medications for 4 weeks prior to visit 1)

• Intention to move out of area within the next 6 months